These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 32182141)

  • 21. The effect of intervention versus watchful waiting on disease progression and overall survival in smoldering multiple myeloma: a systematic review of randomized controlled trials.
    Ojo AS; Ojukwu SG; Asemota J; Akinyemi O; Araoye MO; Saleh M; Ali A; Sarma R
    J Cancer Res Clin Oncol; 2022 Apr; 148(4):897-911. PubMed ID: 35059867
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Smoldering multiple myeloma - Past, present, and future.
    Mann H; Katiyar V; Varga C; Comenzo RL
    Blood Rev; 2022 Mar; 52():100869. PubMed ID: 34312016
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How I approach smoldering multiple myeloma.
    Vaxman I; Gertz MA
    Blood; 2022 Aug; 140(8):828-838. PubMed ID: 35576526
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monoclonal gammopathies of unknown significance and smoldering myeloma: Assessment and management of the elderly patients.
    González-Calle V; Mateos MV
    Eur J Intern Med; 2018 Dec; 58():57-63. PubMed ID: 29907380
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Three-dimensional telomere profiling predicts risk of progression in smoldering multiple myeloma.
    Kumar S; Rajkumar SV; Jevremovic D; Kyle RA; Shifrin Y; Nguyen M; Husain Z; Alikhah A; Jafari A; Mai S; Anderson K; Louis S
    Am J Hematol; 2024 Aug; 99(8):1532-1539. PubMed ID: 38747543
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Smoldering multiple myeloma: the role of different scoring systems in identifying high-risk patients in real-life practice.
    Cocito F; Mangiacavalli S; Ferretti VV; Cartia CS; Ganzetti M; Benveuti P; Pompa A; Catalano M; Fugazza E; Landini B; Arcaini L; Corso A
    Leuk Lymphoma; 2019 Dec; 60(12):2968-2974. PubMed ID: 31169049
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective.
    Caers J; Fernández de Larrea C; Leleu X; Heusschen R; Zojer N; Decaux O; Kastritis E; Minnema M; Jurczyszyn A; Beguin Y; Wäsch R; Palumbo A; Dimopoulos M; Mateos MV; Ludwig H; Engelhardt M
    Oncologist; 2016 Mar; 21(3):333-42. PubMed ID: 26921288
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluating early intervention in smoldering myeloma clinical trials: a systematic review.
    Kakkilaya A; Trando A; Cliff ERS; Mian H; Al Hadidi S; Aziz M; Goodman AM; Jeong AR; Smith WL; Kelkar AH; Russler-Germain DA; Mehra N; Chakraborty R; Gertz MA; Mohyuddin GR
    Oncologist; 2024 Sep; ():. PubMed ID: 39236068
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic Advances in the Management of Smoldering Myeloma.
    Khan R; Zahid U; Kollu V; Jahan N; Ali M; Tricot G; Anwer F
    Am J Ther; 2020; 27(2):e194-e203. PubMed ID: 31842112
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Baseline serum B-cell maturation antigen levels predict time to disease progression for patients with smoldering multiple myeloma.
    Bujarski S; Goldwater MS; Regidor BS; Jew S; Daniely D; Swift RA; Eades BM; Emamy-Sadr M; Souther E; Li M; Wang C; Xu N; Chen H; Spektor TM; Berenson JR
    Eur J Haematol; 2021 Sep; 107(3):318-323. PubMed ID: 33993536
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Smoldering Multiple Myeloma: Emerging Concepts and Therapeutics.
    Sundararajan S; Kumar A; Korde N; Agarwal A
    Curr Hematol Malig Rep; 2016 Apr; 11(2):102-10. PubMed ID: 26894382
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical characteristics and outcomes in risk-stratified patients with smoldering multiple myeloma: data from the Czech Republic Registry of Monoclonal Gammopathies.
    Sandecka V; Popkova T; Stork M; Maisnar V; Minarik J; Jungova A; Pavlicek P; Stejskal L; Pospisilova L; Heindorfer A; Obernauerova J; Gregora E; Sykora M; Ullrychova J; Wrobel M; Kessler P; Jelinek T; Kunovszki P; Bathija S; Gros B; Wilbertz S; Cai Q; Lam A; Spicka I
    Blood Cancer J; 2023 Sep; 13(1):153. PubMed ID: 37752128
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Moving From Cancer Burden to Cancer Genomics for Smoldering Myeloma: A Review.
    Maura F; Bolli N; Rustad EH; Hultcrantz M; Munshi N; Landgren O
    JAMA Oncol; 2020 Mar; 6(3):425-432. PubMed ID: 31830214
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
    Korde N; Roschewski M; Zingone A; Kwok M; Manasanch EE; Bhutani M; Tageja N; Kazandjian D; Mailankody S; Wu P; Morrison C; Costello R; Zhang Y; Burton D; Mulquin M; Zuchlinski D; Lamping L; Carpenter A; Wall Y; Carter G; Cunningham SC; Gounden V; Sissung TM; Peer C; Maric I; Calvo KR; Braylan R; Yuan C; Stetler-Stevenson M; Arthur DC; Kong KA; Weng L; Faham M; Lindenberg L; Kurdziel K; Choyke P; Steinberg SM; Figg W; Landgren O
    JAMA Oncol; 2015 Sep; 1(6):746-54. PubMed ID: 26181891
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression.
    Medina-Herrera A; Vazquez I; Cuenca I; Rosa-Rosa JM; Ariceta B; Jimenez C; Fernandez-Mercado M; Larrayoz MJ; Gutierrez NC; Fernandez-Guijarro M; Gonzalez-Calle V; Rodriguez-Otero P; Oriol A; Rosiñol L; Alegre A; Escalante F; De La Rubia J; Teruel AI; De Arriba F; Hernandez MT; Lopez-Jimenez J; Ocio EM; Puig N; Paiva B; Lahuerta JJ; Bladé J; San Miguel JF; Mateos MV; Martinez-Lopez J; Calasanz MJ; Garcia-Sanz R;
    Blood Cancer J; 2024 Apr; 14(1):74. PubMed ID: 38684670
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent Advances in the Management of Smoldering Multiple Myeloma.
    Madhira BR; Konala VM; Adapa S; Naramala S; Ravella PM; Parikh K; Gentile TC
    World J Oncol; 2020 Apr; 11(2):45-54. PubMed ID: 32284772
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis.
    Visram A; Rajkumar SV; Kapoor P; Dispenzieri A; Lacy MQ; Gertz MA; Buadi FK; Hayman SR; Dingli D; Kourelis T; Gonsalves W; Warsame R; Muchtar E; Leung N; Baughn LB; Kyle RA; Kumar S
    Blood Cancer J; 2021 Nov; 11(11):186. PubMed ID: 34836942
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma.
    Sklavenitis-Pistofidis R; Aranha MP; Redd RA; Baginska J; Haradhvala NJ; Hallisey M; Dutta AK; Savell A; Varmeh S; Heilpern-Mallory D; Ujwary S; Zavidij O; Aguet F; Su NK; Lightbody ED; Bustoros M; Tahri S; Mouhieddine TH; Wu T; Flechon L; Anand S; Rosenblatt JM; Zonder J; Vredenburgh JJ; Boruchov A; Bhutani M; Usmani SZ; Matous J; Yee AJ; Jakubowiak A; Laubach J; Manier S; Nadeem O; Richardson P; Badros AZ; Mateos MV; Trippa L; Getz G; Ghobrial IM
    Cancer Cell; 2022 Nov; 40(11):1358-1373.e8. PubMed ID: 36379208
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology.
    Mateos MV; Landgren O
    Cancer Treat Res; 2016; 169():3-12. PubMed ID: 27696254
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The road to treating smoldering multiple myeloma.
    Korde N; Mailankody S; Landgren O
    Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S59-64. PubMed ID: 25486957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.